Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Sharma

Showing results (181-190 of 191) with videos related to

Pageof 20
Sort By:
The Journal of Clinical Investigation|April 1, 1997
A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitroI Inoue, T Nakajima, C S Williams, et al.
Diabetologia|May 29, 2012
Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetesC Andersson, L van Gaal, I D Caterson, et al.
Diabetes, Obesity & Metabolism|August 2, 2008
Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT)A M Sharma, I D Caterson, W Coutinho, et al.
Fortschritte Der Medizin. Originalien|January 22, 2004
[Aim, design and methods of the "Hypertension and diabetes screening and awareness" -- (HYDRA) study]H U Wittchen, P Krause, M Höfler, et al.
Fortschritte Der Medizin. Originalien|January 22, 2004
[Management of diabetes and hypertension: how do primary care physicians judge their performance?]P Krause, H U Wittchen, B Küpper, et al.
Fortschritte Der Medizin. Originalien|January 22, 2004
[Hypertension, diabetes mellitus and comorbidity in primary care]H U Wittchen, P Krause, M Höfler, et al.
Diabetes, Obesity & Metabolism|September 18, 2009
Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trialL F Van Gaal, I D Caterson, W Coutinho, et al.
International Journal of Obesity (2005)|December 19, 2014
Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trialR V Seimon, D Espinoza, N Finer, et al.
Diabetes, Obesity & Metabolism|December 24, 2011
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trialI D Caterson, N Finer, W Coutinho, et al.
Journal of the American Society of Nephrology : JASN|September 7, 1999
Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individualsW Siffert, P Forster, K H Jöckel, et al.
Pageof 20

Showing results (181-190 of 191) with videos related to

Sort By:
Pageof 20
The Journal of Clinical Investigation|April 1, 1997
A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitroI Inoue, T Nakajima, C S Williams, et al.
Diabetologia|May 29, 2012
Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetesC Andersson, L van Gaal, I D Caterson, et al.
Diabetes, Obesity & Metabolism|August 2, 2008
Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT)A M Sharma, I D Caterson, W Coutinho, et al.
Fortschritte Der Medizin. Originalien|January 22, 2004
[Aim, design and methods of the "Hypertension and diabetes screening and awareness" -- (HYDRA) study]H U Wittchen, P Krause, M Höfler, et al.
Fortschritte Der Medizin. Originalien|January 22, 2004
[Management of diabetes and hypertension: how do primary care physicians judge their performance?]P Krause, H U Wittchen, B Küpper, et al.
Fortschritte Der Medizin. Originalien|January 22, 2004
[Hypertension, diabetes mellitus and comorbidity in primary care]H U Wittchen, P Krause, M Höfler, et al.
Diabetes, Obesity & Metabolism|September 18, 2009
Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trialL F Van Gaal, I D Caterson, W Coutinho, et al.
International Journal of Obesity (2005)|December 19, 2014
Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trialR V Seimon, D Espinoza, N Finer, et al.
Diabetes, Obesity & Metabolism|December 24, 2011
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trialI D Caterson, N Finer, W Coutinho, et al.
Journal of the American Society of Nephrology : JASN|September 7, 1999
Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individualsW Siffert, P Forster, K H Jöckel, et al.
Pageof 20